34P The impact of immediate prior therapies (Tx) on the safety and efficacy of telisotuzumab vedotin (Teliso-V) in patients (pts) with advanced c-Met protein–overexpressing (OE) non-squamous (NSQ) EGFR wildtype (WT) NSCLC in the phase II LUMINOSITY study